Summary: Researchers identified an epigenetic factor that influences women’s risk of obesity.
The study found that the risk of obesity increases by 44% if there are a large number of methyl groups attached to the POMC gene, associated with the feeling of satiety. This kind of DNA “formatting” or epigenetic marking occurs early during the embryonic stage.
Although other factors like socioeconomic status and lifestyle also influence obesity risk, this study highlights the role of epigenetic factors in the propensity to gain excess weight.
Key Facts:
- Epigenetic marking of the POMC gene, responsible for the feeling of satiety, affects the risk of obesity in women.
- This “formatting” of the gene takes place very early on during embryonic development.
- Although the impact of nutrition on methylation of the POMC gene seems to be limited, early lab studies suggest that drugs can be developed to target this epigenetic change to help manage obesity.
Source: Charite
What determines whether we become overweight? Aside from lifestyle, predisposition plays a role, but genes cannot fully explain the inherited propensity to accumulate excess weight.
A new study by Charité – Universitätsmedizin Berlin in Science Translational Medicine shows that a kind of formatting of the DNA code in one gene that is associated with satiety is implicated in a slightly elevated risk of excess body weight – at least in women. This “epigenetic marking” is established early on during the embryonic stage.
People who are overweight, especially those who are severely overweight, are at increased risk of a number of serious diseases such as cardiovascular disease, diabetes, and cancer. It is a growing health issue.
All over the world, the number of overweight people is increasing. In the European Region, two out of three adults (59 percent) are overweight or obese, according to the World Health Organization.
But what determines whether people will become overweight? Genetic predisposition plays a major role, alongside lifestyle. The similarity of the body mass index (BMI) in identical twins ranges from 40 to 70 percent. Even identical twins raised in different families still show the same significant similarity.
Scientists have identified several genetic variants that influence a person’s body weight – and with it, the risk of developing obesity. But even taken all together, they cannot explain the heritability that has been observed. Researchers began to suspect there must be additional non-genetic factors that affect a person’s propensity to gain excess weight.
Satiety gene is not altered, but formatted
Researchers led by Prof. Peter Kühnen, Director of the Department of Pediatric Endocrinology at Charité, have now identified one such factor in their recent study.
According to their findings, women’s risk of being overweight increases by about 44 percent if there are an especially large number of methyl groups adhering to the POMC (pro-opiomelanocortin) gene, which is responsible for the feeling of satiety.
Methyl groups are tiny chemical units the body uses to mark the letters in the DNA code to activate or deactivate genes without modifying the sequence of letters in the DNA. In other words, the effect is much like highlighting a section of a text without rewriting the text itself. This type of “DNA formatting” is known as epigenetic marking.
For their study, the team of researchers analyzed the “formatting” of the POMC gene in more than 1,100 people. They found more methyl groups attached to the satiety gene in obese women with a BMI of over 35 than in women with normal body weight.
“A 44 percent increase in the risk of obesity is about the same as the effect that has been observed for individual gene variants as well,” says Kühnen.
“By comparison, socioeconomic factors have a much stronger effect. They can increase the risk by a factor of two to three. As for why the methylation effect only shows up in women, we don’t know yet.”
The POMC gene is “formatted” very early on during embryonic development, as the researchers showed by comparing methylation patterns in more than 15 sets each of identical and fraternal twins.
While the “formatting” of the satiety gene was the same in most of the identical twins, there was hardly any correlation in the fraternal twins.
“This indicates that the epigenetic marking of the POMC gene is established shortly after the egg and sperm cells merge, before the fertilized egg divides into two twin embryos,” explains Lara Lechner, the study’s first author, who works at the Department of Pediatric Endocrinology. This means the very early stage of pregnancy is crucial.
What influences formatting?
But what influences how much methylation the satiety gene undergoes – and thus, the risk that a person will become overweight? Past studies indicated that the presence or absence of certain nutrients that supply methyl groups could have an effect on epigenetic processes. These nutrients include betaine, methionine, and folic acid, all of which are typically absorbed through a person’s diet.
A newly developed method involving individual human stem cells allowed the Charité researchers to simulate in the lab how the methylation pattern is determined during embryonic development and how nutrients affect it.
“On the one hand, our studies and others as well show that folic acid, betaine, and other nutrients have a limited effect on the extent of methylation,” Kühnen notes.
“We’ve observed that the ‘DNA formatting system’ is very stable on the whole, with cells compensating for minor fluctuations in the nutrient supply.
“On the other hand, there are indications that the variability of this ‘formatting’ develops at random. That means that it is not possible – not yet, at any rate – to externally influence whether a person has more or less methylation in the POMC region.”
Medications may help
At least in theory, women who are at elevated risk of developing obesity due to methylation of the POMC gene could receive medications to help them lose weight, as initial studies of four severely obese women and one man with this exact type of “formatting” of the satiety gene suggest.
The subjects were given a specific drug that curbs the feeling of hunger and has already been approved to treat obese patients with a mutation of the POMC gene. Within three months after starting treatment, all five patients experienced less hunger.
They lost an average of seven kilograms, or about five percent of their body weight. Some of them continued the treatment and continued to lose weight.
“These findings show, for a start, that a POMC gene that has undergone epigenetic changes can in fact potentially be addressed through medication,” Kühnen says.
“Further large controlled studies will be needed to show whether treatment with this drug would also be effective over a longer period, and if so, how effective and how safe this type of treatment is. Overall, though, a medication like this would still need to be just one piece of a holistic treatment strategy.”
About the study
Prof. Peter Kühnen, who led the study, is the Director of the Department of Pediatric Endocrinology at Charité. He holds a Heisenberg Professorship and received the Paul Martini Prize, which comes with 50,000 euros in award money, in 2020 for his work on normalizing body weight.
Funding: The current study arose under the auspices of a Consolidator Grant from the European Research Council (ERC), which Kühnen obtained to study the role of epigenetic variability in the emergence of metabolic and endocrine disorders (E-VarEndo). Other sources of funding for the team’s work included the German Research Foundation (DFG), the SPARK-BIH program at the Berlin Institute of Health at Charité (BIH), and a BIH doctoral stipend.
About this genetics and obesity research news
Author: Manuela Zingl
Source: Charite
Contact: Manuela Zingl – Charite
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment” by Peter Kühnen et al. Science Translational Medicine
Abstract
Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment
Increasing evidence points toward epigenetic variants as a risk factor for developing obesity.
We analyzed DNA methylation of the POMC (pro-opiomelanocortin) gene, which is pivotal for satiety regulation. We identified sex-specific and nongenetically determined POMC hypermethylation associated with a 1.4-fold (confidence interval, 1.03 to 2.04) increased individual risk of developing obesity.
To investigate the early embryonic establishment of POMC methylation states, we established a human embryonic stem cell (hESC) model. Here, hESCs (WA01) were transferred into a naïve state, which was associated with a reduction of DNA methylation.
Naïve hESCs were differentiated via a formative state into POMC-expressing hypothalamic neurons, which was accompanied by re-establishment of DNA methylation patterning.
We observed that reduced POMC gene expression was associated with increased POMC methylation in POMC-expressing neurons.
On the basis of these findings, we treated POMC-hypermethylated obese individuals (n = 5) with an MC4R agonist and observed a body weight reduction of 4.66 ± 2.16% (means ± SD) over a mean treatment duration of 38.4 ± 26.0 weeks.
In summary, we identified an epigenetic obesity risk variant at the POMC gene fulfilling the criteria for a metastable epiallele established in early embryonic development that may be addressable by MC4R agonist treatment to reduce body weight.
